[HTML][HTML] A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …
[HTML][HTML] Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
X Chi, X Liu, C Wang, X Zhang, X Li, J Hou… - Nature …, 2020 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads worldwide and
leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide …
leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide …
Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …
[PDF][PDF] A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …
variants with increased transmissibility and potential resistance, antibodies and vaccines …
[HTML][HTML] Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
V Dussupt, RS Sankhala, L Mendez-Rivera… - Nature …, 2021 - nature.com
Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …
[HTML][HTML] A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
T Noy-Porat, E Makdasi, R Alcalay, A Mechaly… - Nature …, 2020 - nature.com
The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically …
[HTML][HTML] A potently neutralizing antibody protects mice against SARS-CoV-2 infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions
of infections and hundreds of thousands of deaths globally. There are no widely available …
of infections and hundreds of thousands of deaths globally. There are no widely available …
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
Z Lv, YQ Deng, Q Ye, L Cao, CY Sun, C Fan, W Huang… - Science, 2020 - science.org
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health …
syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health …
[PDF][PDF] Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …
[HTML][HTML] Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
Immediately from the outset of the COVID-19 pandemic, researchers from diverse
biomedical and biological disciplines have united to study the novel pandemic virus, SARS …
biomedical and biological disciplines have united to study the novel pandemic virus, SARS …